logo-loader
RNS
Ananda Pharma Plc

Ananda Pharma PLC - Redemption of Unsecured CLNs and Director Dealing

RNS Number : 0712K
Ananda Pharma PLC
03 December 2025
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU, WHICH IS PART OF UNITED KINGDOM DOMESTIC LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

A logo with blue and green dots Description automatically generated

03 December 2025

 

ANANDA PHARMA PLC 

("Ananda" or the "Company") 

 

Redemption of Unsecured Convertible Loan Notes and Director Dealing

 

Ananda Pharma plc (AQSE: ANA, OTC: ANANF),  a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, announces the automatic redemption of the 600,000 of £1 each denomination unsecured, interest bearing convertible loan notes (the "CLNs") issued by the Company in September 2023 (https://investors.anandapharma.co.uk/announcements/5456547). The Company has issued 150,000,000 Ordinary Shares at a deemed conversion price of £0.004 per Ordinary Share. The accrued interest of £233,843.02 will remain as unsecured debt. As Charles Morgan was the holder of 300,000 CLNs, he will become interested in a further 75,000,000 Ordinary Shares.

Holding in Company

Following the issue of the 75,000,000 Ordinary Shares pursuant to the Convertible loan note redemption, Mr Charles Morgan will hold 2,503,875,896 Ordinary Shares representing 56.28 per cent. of the share capital as enlarged by the issue of the Ordinary Shares to satisfy the CLN redemption, as detailed above.

The Company announced on 24 November 2025 that it would be seeking approval from its shareholders to delist from the Aquis exchange. If shareholders approve the delisting at the general meeting to be held on 12 December 2025, then the delisting will be effective at 8.00 a.m. on 22 December 2025.

Admission and Total Voting Rights

An application has been made to the Aquis Stock Exchange for 150,000,000 Ordinary Shares to be admitted to trading on AQSE with effect from 8 a.m. on or around 9th December 2025 ("Admission"). The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

Following Admission, the Company will have 4,449,146,581 Ordinary Shares in issue, each share carrying the right to one vote. This figure of 4, 449,146,581 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

About Ananda Pharma

Ananda Pharma (AQSE: ANA) is a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, including endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR).  The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh.

 

For more information, please visit our website:

 

To stay up to date with Ananda's news please follow our social media channels:  

  

·              Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93

·              Instagram: https://www.instagram.com/anandapharmaplc/

·              LinkedIn:  https://www.linkedin.com/company/anandapharma

·              X: https://twitter.com/AnandaPlc

  

-Ends-

  

For the purposes of UK MAR, the Directors of the Company accept responsibility for the contents of this announcement.  

  

ANANDA PHARMA PLC 

+44 (0)7463 686 497 


ir@anandapharma.co.uk

 

Chief Executive Officer 


Melissa Sturgess 




Finance Director 


Jeremy Sturgess-Smith 


 


SP ANGEL CORPORATE FINANCE LLP 


 


Corporate Finance 

+44 (0)20 3470 0470 

Richard Morrison 


Josh Ray


 


Corporate Broking 

+44 (0)20 3470 0534

Vadim Alexandre

Vadim.alexandre@spangel.co.uk

Abigail Wayne 

Abigail.wayne@spangel.co.uk

Rob Rees 

 

Rob.rees@spangel.co.uk



 

 

https://investors.anandapharma.co.uk/link/r8KmGe

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Charles Morgan

2

Reason for the notification

a)

Position/status

Chairman

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor

a)

Name

Ananda Pharma plc

b)

LEI

894500DFM8VOC5FW4X47

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

 

Ordinary Shares of 0.2p each

 

 

ISIN: GB00BDQPXQ60

b)

Nature of the transaction

Issue of Ordinary Shares from CLN conversion

c)

Price(s) and volume(s)

Date

Price (p)

Volume

1.12.24

0.4

75,000,000


d)

Aggregated information

- Aggregated volume

- Price

 

 

75,000,000 Ordinary Shares

£0.004 per Ordinary Share

e)

Date of the transaction

1 December 2025

f)

Place of the transaction

AQSE

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXGCBDDRXGDGUX
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read